According to a recent report published by PharmSource Information Services, growth of the pharma/biopharma contract manufacturing sector is likely to continue to slow relative to overall industry growth despite the significant increase in New Active Substances launched from 2014 onwards. Key reasons for the slowing industry growth rate, according to the report, are the appreciation of the U.S. dollar against the Euro, client losses and regulatory compliance issues.   The new report, Contract D...